VYGR
VYGR clinical trials: Voyager Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Voyager Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 3
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
VYGR on the catalyst calendar · VYGR registry changes
- Primary completion Apr 28, 2029Sponsor estimatePhase 1NCT07764146An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's DiseaseVoyager Therapeutics · Alzheimer s DiseaseRecruitingVYGRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2026ActualPhase 1/Phase 2NCT06874621VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's DiseaseVoyager Therapeutics · Alzheimer's Disease (AD)Active, not recruitingVYGRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2024Sponsor estimatePhase 1NCT04885114Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's DiseaseVoyager Therapeutics · Huntington DiseaseWithdrawnVYGRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2024ActualPhase 1NCT03562494VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)Neurocrine Biosciences · Parkinson's DiseaseCompletedNBIXLeadVYGRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 18, 2023ActualNo phase registeredNCT03733496Observational, Long-term Extension Study for Participants of Prior VY-AADC01 StudiesNeurocrine Biosciences · Parkinson's DiseaseCompletedNBIXLeadVYGRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 10, 2021ActualPhase 1NCT03065192Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's DiseaseNeurocrine Biosciences · Idiopathic Parkinson's DiseaseCompletedNBIXLeadVYGRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 24, 2020ActualPhase 1NCT01973543Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's DiseaseNeurocrine Biosciences · Parkinson's DiseaseCompletedNBIXLeadVYGRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner